News Headlines

  1. Aptevo Therapeutics Begins Phase 1 Clinical Trial Of APVO210 A Novel Bispecific Antibody For The Treatment Of Autoimmune And Inflammatory Diseases
    3/20/2019

    Aptevo Therapeutics Inc. (Nasdaq: APVO), a biotechnology company focused on developing novel oncology, autoimmune and hematology therapeutics, announced today that it has commenced dosing in a Phase 1 clinical trial of APVO210, a novel bispecific antibody candidate built on Aptevo’s ADAPTIR™ therapeutic protein platform which is being developed to treat autoimmune and inflammatory diseases.

  2. WCG Introduces A Transformational Solution For Clinical Research Sites
    3/19/2019

    WIRB-Copernicus Group® (WCG™) introduces WCG SiteReady™, a first-of-its-kind solution aimed at increasing the efficiency and profitability of clinical research for institutions and independent research sites. WCG’s newest offering helps researchers to optimize their performance, gain a competitive edge, and attract more opportunities for externally-funded clinical trials.

  3. CRF Bracket Supports Remote Consenting For Virtual Clinical Studies With Latest Release Of Its Integrated eConsent Solution
    3/19/2019

    CRF Bracket announced a new release of TrialConsent®, the latest version of its revolutionary eConsent solution, with enhanced capabilities to support remote consenting in virtual clinical trials.

  4. Crinetics Pharmaceuticals Doses First Patients In Phase 2 Clinical Trials Of CRN00808 For Acromegaly
    3/19/2019

    Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the dosing of the first patients in the ACROBAT EVOLVE and EDGE trials for CRN00808 in patients with acromegaly.

  5. Rain Therapeutics Announces First Patient Dosed In Phase 2 Trial Of Tarloxotinib For The Treatment Of Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Or HER2-Activating Mutations
    3/19/2019

    Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced that it has dosed the first patient in its Phase 2 clinical trial of tarloxotinib (Tarlox).

  6. CytoDyn Reaches Historical Milestone, Submits First Of Three Sections Of BLA To FDA For Leronlimab (PRO 140) As A Combination Therapy For HIV
    3/18/2019

    CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has filed with the U.S. Food and Drug Administration (FDA) the non-clinical portion of its Biologics License Application (BLA) using the FDA’s Rolling Review process.

  7. Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement To Fund Initiation Of The First Phase 3 Celiac Disease Clinical Trial
    3/18/2019

    Innovate Biopharmaceuticals, Inc. (“Innovate” or the “Company”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation therapeutics, announced that on March 17, 2019, it entered into an agreement (the “Agreement”) with SDS Capital Partners II LLC and certain other accredited investors (together, the “Purchasers”) providing for the sale by the Company at a purchase price of $2.33 per share as further described below of up to 4,291,845 shares (the “Shares”) of its common stock (the “Common Stock”), up to 2,575,107 five-year term warrants with an exercise price as further described below at a premium to the purchase price and up to 4,291,845 12-month term warrants at an exercise price of $4.00 (total of up to 6,866,952 shares of Common Stock).

  8. EMA Grants Orphan Medicinal Product Designation For Retrotope’s RT001 In The Treatment Of Infantile Neuroaxonal Dystrophy (INAD), A PLA2G6 Associated Neurodegeneration (PLAN)
    3/13/2019

    Retrotope received notification from the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) that its request for orphan medicinal product designation for the treatment of INAD with RT001, a chemically-fortified polyunsaturated fatty acid drug, has been granted by the European Commission.

  9. aTyr Pharma Announces Research Collaboration With Global Biotherapeutics Leader CSL Behring
    3/11/2019

    aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has entered into a research collaboration and option agreement with global biotherapeutics leader CSL Behring, for the development of product candidates derived from up to four tRNA synthetases from aTyr’s preclinical pipeline.

  10. ProQR Doses First Patient In Phase 1/2 STELLAR Trial Of QR-421a For Usher Syndrome Type 2
    3/11/2019

    ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are expected to be announced mid-2019.